CYX Cytomyx Hldgs

RNS Number:8340I
Cytomyx Holdings PLC
21 February 2005


For immediate release                                           21 February 2005


                              CYTOMYX HOLDINGS PLC

                          ("Cytomyx" or "the Company")

                        Annual General Meeting Statement


The Annual General Meeting of Cytomyx Holdings plc (AIM: CYX), the leading
provider of drug discovery products and services, was held today and all of the
resolutions put before the meeting were passed unanimously.

Dr Bill Mason, Chairman of Cytomyx, made the following statement to
shareholders: "The Directors are particularly pleased with the progress that has
been made in the Cytomyx Limited business with regard to its ion channel
technologies. Over the course of the year, around 18 new high value cell lines
have been launched with strong sales from within the pharmaceutical industry.
This is expected to continue strongly in the current financial year. Analysis of
the sales profile of the company's products also showed an encouraging growth in
export sales to the US, Europe and Rest of the World.

"Over the current year, Cytomyx Limited intends also to strengthen its
commercial activities in the US to exploit further its new high value products
including tissue microarrays. It has recently appointed Dr Rod Westrop as its
new Commercial Director to take control of these activities. Clinomics
Biosciences has now been integrated with Cytomyx Limited creating a single
business unit focussed on solutions that enhance drug discovery productivity.

"In the course of the year, Cytomyx has also announced a new $2.5m funding
arrangement with Laurus Fund Managers of New York, reflecting the strong
interest in the company's activities from the US following its acquisition of
Clinomics Biosciences, the tissue microarray company.

"The Directors look forward to the coming year with confidence given the
opportunities that are available to the business in its target markets."



For further information, please contact:
Cytomyx Holdings plc                                            01223 508191
Mike Kerins, Chief Executive

Buchanan Communications                                        020 7466 5000
Mark Court/Mary-Jane Johnson

The Wall Street Group                                        +1 212 888 4848
Ron Stabiner



Notes for editors

About Cytomyx Holdings plc

Cytomyx Holdings plc is a rapidly growing life science company based in
Cambridge, UK. Its four operating subsidiaries - Cytomyx Ltd, Clinomics
Biosciences, Inc., Cambridge BioScience Ltd and Cytocell Technologies Ltd -
develop and market a wide range of products and services to the pharmaceutical,
diagnostics and academic research markets. Cytomyx is listed on the AIM market
of the London Stock Exchange. For more information please visit
www.cytomyx-holdings.com


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END
AGMTBMTTMMITBMA

Cytomyx (LSE:CYX)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024

Cytomyx (LSE:CYX)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024